Price$1.32+0.02 (+1.92%)
04:30 PM07:30 PM
News · 26 weeks40+700%
2026-01-182026-07-12
Mix1890d
- Insider8(44%)
- SEC Filings5(28%)
- Earnings2(11%)
- Other2(11%)
- Analyst1(6%)
Latest news
25 items- INSIDERDirector Wan Mark A was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERDirector Todisco Joseph was granted 5,100 shares, increasing direct ownership by 80% to 11,497 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERDirector Jain Abhinav was granted 5,100 shares, increasing direct ownership by 70% to 12,412 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERDirector Hoffman Stephen J was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERDirector Broadfoot Jill Marie was granted 5,100 shares, increasing direct ownership by 60% to 13,647 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERDirector Bozilenko Marina was granted 5,100 shares, increasing direct ownership by 56% to 14,147 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERDirector Adams Adrian was granted 5,100 shares, increasing direct ownership by 29% to 22,709 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- SECTalphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- ANALYSTH.C. Wainwright resumed coverage on Talphera with a new price targetH.C. Wainwright resumed coverage of Talphera with a rating of Buy and set a new price target of $3.00
- INSIDERChief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes4 - TALPHERA, INC. (0001427925) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)
- SECSEC Form 10-Q filed by Talphera Inc.10-Q - TALPHERA, INC. (0001427925) (Filer)
- SECTalphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- PRTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateNEPHRO CRRT clinical study expected to be completed this yearCash and investments of $21.1 million at March 31, 2026Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ETSAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update."In early March, we announced the attainment of 50% enrollment in the NEPHRO CRRT study evaluating nafamostat. With continued steady enrollment, we have well exceeded this level,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)
- PRTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.Webcast InformationThe webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted
- SECSEC Form DEFA14A filed by Talphera Inc.DEFA14A - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form DEF 14A filed by Talphera Inc.DEF 14A - TALPHERA, INC. (0001427925) (Filer)
- INSIDERSEC Form 4 filed by Angotti Vincent J.4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Asadorian Raffi4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Aslam Shakil4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Dasu Badri N4 - TALPHERA, INC. (0001427925) (Issuer)
- SECSEC Form EFFECT filed by Talphera Inc.EFFECT - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form 424B7 filed by Talphera Inc.424B7 - TALPHERA, INC. (0001427925) (Filer)
- INSIDERSEC Form 4 filed by Angotti Vincent J.4 - TALPHERA, INC. (0001427925) (Issuer)
TLPH FAQ
6 questionsWhere does TLPH stock trade?
Talphera Inc. (TLPH) is listed on NASDAQ.What sector and industry is TLPH in?
Talphera Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Talphera Inc. go public?
Talphera Inc. (TLPH) completed its IPO in 2011.What are analysts saying about TLPH?
Talphera Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2026-06-05. Recent price targets range from $300.00 to $400.00.What companies are similar to TLPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TLPH side-by-side with any of them on Quantisnow.How can I track TLPH on Quantisnow?
Quantisnow aggregates Talphera Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLPH to receive live email and push alerts on every new disclosure.